Evaluation of Clinical Laboratory Metrics in Adolescents with Moderate-to-Severe Atopic Dermatitis Receiving Tralokinumab for Up to 52 Weeks in the Phase 3 ECZTRA 6 Study - Poll - MDSpire

Evaluation of Clinical Laboratory Metrics in Adolescents with Moderate-to-Severe Atopic Dermatitis Receiving Tralokinumab for Up to 52 Weeks in the Phase 3 ECZTRA 6 Study

  • By

  • Amy S. Paller

  • Michael J. Cork

  • H. Chih-ho Hong

  • Weily Soong

  • Shannon K. R. Schneider

  • Hannah Lo

  • Frank Vinther

  • Patrick Thøgersen

  • Andreas Wollenberg

  • April 25, 2026

  • 0 min

Share

Original Source(s)

Evaluation of Clinical Laboratory Metrics in Adolescents with Moderate-to-Severe Atopic Dermatitis Receiving Tralokinumab for Up to 52 Weeks in the Phase 3 ECZTRA 6 Study

  • by Amy S. Paller, Michael J. Cork, H. Chih-ho Hong, Weily Soong, Shannon K. R. Schneider, Hannah Lo, Frank Vinther, Patrick Thøgersen, Andreas Wollenberg

  • April 25, 2026

Related Content

Overview of President Trump’s Executive Actions Impacting LGBTQ+ Health

Exploring Androgenetic Alopecia in Transgender and Gender-Diverse Populations: Insights on Characterization and Treatment Approaches

Paradoxical inflammatory switches during biologic therapy: a mechanistic framework, clinical algorithm, and pediatric illustrations